
CELL & GENE THERAPY REVOLUTION

Building for impact

in partnership
with



CELL & GENE
CONSULTING

April 7 to 9, 2026 - Sheraton Laval &
Convention Center, Laval, QC, Canada

KNOWLEDGE – MOBILIZATION – ACTIONS

WWW.CELLCAN.COM/FORUM2026

SPECIAL ACKNOWLEDGEMENTS

SCIENTIFIC COMMITTEE

Denis Claude Roy, Chief Executive Officer, CellCAN

Domhnall McGowan, Chief Training Officer, CATTI

Arnaud Deladeriere, Cell&Gene Consulting inc.

ORGANIZING COMMITTEE

Vanessa Laflamme, Chief Operating Officer, CellCAN

Fanny Laferrière, Executive Assistant & Logistics Coordinator, CellCAN

Mathieu Lavallée, Founding President, Exponentiel Conseil

Isabelle Baril, Assistant to the Director, Hematology-Oncology
and Cell Therapy University Institute (IHOT)

EVENT COORDINATION TEAM

Tabasko

Branding and artistic production

www.tabasko.ca

Exponentiel Conseil

Communications and public relations

www.exponentielconseil.com

Onyris

Web solutions

www.onyris.com

Sheraton Laval & Convention Center

Facilities, hospitality and banquet services

www.marriott.com

THANK YOU FOR MAKING THIS EVENT A SUCCESS!

WELCOME WORD FROM CELLCAN



Chers délégués,

Je suis fier de vous accueillir au quatrième Forum stratégique pancanadien de CellCAN sur la Révolution de la thérapie cellulaire et génique : construire pour avoir un impact qui se tient à Laval, Québec. Avec près de 35 conférenciers de renommée mondiale, le Forum est un rendez-vous incontournable pour réseauter et s'informer sur les thérapies avancées au Canada et dans le monde.

En partenariat avec CATTI et Cell & Gene Consulting, le Forum stratégique de cette année réunira des leaders des milieux scientifiques, industriels et politiques afin de tracer la voie du Canada dans le paysage mondial de la thérapie cellulaire et génique. Nous nous pencherons sur les forces qui façonnent l'avenir de notre domaine. Nous explorerons comment l'AI passe du battage médiatique à un impact réel, comment surmonter les obstacles à la fabrication et évoluer efficacement, comment débloquer l'accès au marché dans un environnement soucieux des coûts, et comment développer les talents et les infrastructures dont le Canada a besoin pour mener la révolution de la thérapie cellulaire et génique jusqu'en 2030.

Nous avons la chance d'accueillir deux conférenciers de renom durant la préconférence. Madame Sharon Anderson, vice-présidente des affaires scientifiques à l'Alliance for Regenerative Medicine fera le point sur la situation de l'industrie des thérapies cellulaires et géniques. Dr Kevin Hay, chercheur clinique à l'Université de Calgary et Institut Charbonneau du cancer nous présentera comment la thérapie CAR-T peut être un catalyseur de l'innovation en immunothérapie au Canada.

Au nom du conseil d'administration de CellCAN, de notre incroyable équipe de direction et de l'ensemble des comités scientifique et organisateur, je voudrais remercier nos conférenciers, nos précieux partenaires et commanditaires, et enfin et surtout, vous, qui participez à cette révolution. Je vous souhaite à tous un événement riche en enseignements, de nouveaux partenariats et d'excellentes discussions.

Dear attendees,

I am proud to welcome you to CellCAN's fourth Pan-Canadian Strategic Forum on "The Cell and Gene Therapy Revolution: Building for Impact," taking place in Laval, Quebec. With nearly 35 world-renowned speakers, the Forum is an essential event for networking and learning about advanced therapies in Canada and around the world.

In partnership with CATTI and Cell & Gene Consulting, this year's Strategic Forum will bring together leaders from the scientific, industrial, and political communities to chart Canada's course in the global landscape of cell and gene therapy. We will examine the forces shaping the future of our field. We will explore how AI is moving from hype to real-world impact, how to overcome manufacturing barriers and scale effectively, how to unlock market access in a cost-conscious environment, and how to develop the talent and infrastructure Canada needs to lead the cell and gene therapy revolution through 2030.

We are pleased to welcome two renowned speakers during the pre-conference. Ms. Sharon Anderson, Vice President of Scientific Affairs at the Alliance for Regenerative Medicine, will provide an overview of the state of the cell and gene therapy industry. Dr. Kevin Hay, a clinical researcher at the University of Calgary and the Charbonneau Cancer Institute, will discuss how CAR-T therapy can serve as a catalyst for innovation in immunotherapy in Canada.

On behalf of the CellCAN Board of Directors, our incredible leadership team, and the entire Scientific and Organizing Committees, I would like to thank our speakers, our valued partners and sponsors, and last but not least, you, who are part of this revolution. I wish you all an event rich in learning, new partnerships, and excellent discussions.

BUILDING CANADA'S BIOMANUFACTURING WORKFORCE



Delivering industry-aligned training to accelerate careers and build GMP-ready teams.

The Canadian Advanced Therapies Training Institute (CATTI) provides hands-on and virtual training designed for efficient, practical upskilling in biomanufacturing, supporting both individuals and organizations across the sector.




Contact us now to learn how CATTI's online and onsite programs can support your workforce goals.



For training inquiries contact info@catti.ca

 catti.ca



25 Years of Transforming Lives Through Regenerative Medicine

For a quarter century, the Stem Cell Network has played a distinct, nationally unifying role: supporting world-class regenerative medicine research, advancing clinical translation, training the next generation of talent, and strengthening Canada's position as a global leader in the field.

Discover the impact
Join us for the next 25



BOOST CELL & GENE THERAPY EFFICIENCY WITH ADVANCED QUALITY TESTING



Streamline
Workflows




Enhance
Manufacturing
Efficiencies



Provide Accurate,
Actionable
Results

FLOOR PLAN



PRECONFERENCE PROGRAM | APRIL 7

17:30 – 18:00	State of CGT industry briefing Sharon Anderson, VP of Scientific Affairs The Alliance for Regenerative Medicine	Laval 3
18:00 – 18:30	CAR-T as a Catalyst: Canada's Pathway to Immunotherapy Innovation Kevin Hay, Clinical Scientist at the University of Calgary and Charbonneau Cancer Institute	Laval 3
18:30 – 21:00	Welcome reception	Lavalloise

CONFERENCE PROGRAM | APRIL 8 - DAY 1

07:30 – 08:30	Registration, breakfast & networking	
09:00 – 09:30	Opening remarks Denis Claude Roy, CEO CellCAN, Director, IHOT	Laval 1&2
09:30 – 12:00	Theme 1: From Data to Design – AI's Role in Accelerating CGT Development Laurent Tillement	
09:30 – 10:00	AI in CGT: hype, hope, or real impact? Irene Rombel, CEO and Co-founder, BioCurie	Laval 3
10:00 – 10:30	AI for In-Process Control and Manufacturing Ohad Karnieli, Founder & CEO, Adva Biotechnology	Laval 3
10:30 – 11:00	Coffee break & networking	Lavalloise
11:00 – 11:30	Introducing automated techniques to improve the results of environmental monitoring Laurent Leblanc, 3P Ecosystem R&D Senior Manager, bioMérieux	Laval 3
11:30 – 12:00	Panel discussion Irene Rombel, Ohad Karnieli, Laurent Leblanc	Laval 3
12:00 – 13:30	Lunch and networking	Laval 1&2

Sponsored by



CONFERENCE PROGRAM | APRIL 8 - DAY 1

13:30 – 17:00	Theme 2: The Great Bottleneck – Commercial-Ready Manufacturing Moderator: Michael May	
13:30 – 15:00	Building the pipeline – How cell therapies are being translated to the clinic in Canada Gayle Piat, ACTM Nicole Prokopishyn, Alberta Precision Labs Michael May, CCVP Eric Lee, BMC Ottawa Steven Pareskevas, Islet Lab, MUHC Martin Giroux, CETC Dr Simon Turcotte, CHUM Lucie Germain, LOEX/CMDGT Elizabeth Csaszar, UHN Center Vancouver Center Victoria Center	Laval 3
15:00 – 15:30	Coffee break & networking	Lavalloise
15:30 – 16:00	Building a National Strategy for the Sustainable Integration of Immunotherapies Jean-Sébastien Delisle, Director ThéCell Medical Director, CETC	Laval 3 Sponsored by  Réseau de thérapie cellulaire, tissulaire et génique du Québec
16:00 – 16:30	Immunotherapy modalities (auto, allo, in vivo) - Capacity and COGs Matthew Hewitt, Charles River Laboratories	Laval 3
16:30 – 17:00	Develop your product with the end in mind: how to fit commercial scale in your design from Day 1 Donna Rill, Chief Technology Officer, Diakonon Oncology	Laval 3
17:00 – 17:20	Panel discussion Jean-Sébastien Delisle, Matthew Hewitt, Donna Rill	Laval 3
17:30 – 19:00	Networking event	Lavalloise Sponsored by 

CONFERENCE PROGRAM | APRIL 9 - DAY 2

07:30 – 08:30	Registration, breakfast & networking	Laval 1&2
15:00 – 15:30	Theme 3: Market Access and Reimbursement in a Budget-Constrained Era Moderator: Benoît Larose Special introduction: Stephane Boyer , Maire de Laval	
08:45 – 09:15	How are price tags determined? Alice Dragomir , Director, Réseau québécois de recherche sur les médicaments	Laval 3
09:15 – 09:45	Innovative pricing models: can it work and for whom? Michèle de Guise , President and CEO, INESSS France Mignault	Laval 3
09:45 – 10:10	Coffee break & networking	Lavalloise
10:10 – 10:40	Enabling affordable access of CAR-T and other cellular gene therapies Boro Dropulić , Executive Director of Caring Cross and CEO of Vector BioMed	Laval 3
10:40 – 11:10	Panel discussion Alice Dragomir , Michèle de Guise , France Mignault , Boro Dropulić	Laval 3
11:10 – 16:45	Theme 4: Strengthening the Canadian Infrastructure for the 2030 Pipeline Moderator: Rob Henderson , CEO	
11:10 – 12:20	Workforce planning 2.0: training centers, credentialing, and retention Domhnall McGowan , CATTI Yoo Jin Park , BioHubNet	Laval 3 Sponsored by 
12:20 – 13:30	Lunch & networking	Laval 1&2

CONFERENCE PROGRAM | APRIL 9 - DAY 2

11:15 – 16:45	Theme 4: Strengthening the Canadian Infrastructure for the 2030 Pipeline (continue) Patrycja Thompson	
13:30 – 14:00	Kasondra White , A/Director General, Health Emergency Readiness Canada	Laval 3
14:00 – 14:30	Patrycja Thompson , Director of Strategy & Operations, The Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toronto, Hub's perspective	
14:30 – 15:00	Coffee break & networking	Lavalloise
15:00 – 16:00	Panel = Public-private partnerships: Canada's force? Chris Rudd , startup Max Paganelli , CEO, Morphocell TBC , BMC	Laval 3
16:00 – 17:00	Panel = Seizing the opportunity for Canada Yvan Côté , CEO, C3i Cedric Heroux , CEO, Biodextris Neil Blackburn , Senior Director, Process Sciences & Analytical Development, OmniaBio	Laval 3
16:00	End of Forum	

SPONSORS

THANKS TO OUR SPONSORS

PLATINUM



GOLD



SILVER



BRONZE



SUPPORTERS



JOIN CELLCAN: CONTRIBUTE TO PUT KNOWLEDGE INTO ACTION

Use #CellGeneRev to join the online conversation

THANK YOU FOR YOUR PARTICIPATION



5415, boulevard L'Assomption
Montréal (Québec) H1T 2M4

www.cellcan.com
info@cellcan.com